Vienna, Austria: – Recombinant protein specialist manufacturer enGenes Biotech GmbH (enGenes) will be one of the innovative small to medium sized enterprises (SMEs) participating in the EU-funded SynBIOcarb program.
SynBIOcarb is the project name for the Marie Skłodowska-Curie Action (MSCA) Innovative Training Network (H2020-MSCA-ITN) that brings together 15 early stage researchers working in PhD projects to bring forward different aspects of the emerging field of Synthetic Glycobiology towards applications in diagnostics and targeted delivery.
Early stage research
This diverse team of chemists, structural biologists, biophysicists, cell biologists and protein engineers are all supported by the EU-funded European Training Network. The project brings together five leading academic and research organisations from the UK, France, Germany, Denmark, and Slovakia, as well as enGenes and three other companies also leading industrial innovation in glycoscience-, protein- and bio-engineering. All will benefit from having the ESRs on their research teams.
The ‘beneficiary’ organizations will provide the ESRs with advanced scientific training in enabling technologies that underpin the development and exploitation of glycoscience for diagnostics and targeted drug delivery.
“The practical scientific training we are giving these young researchers is complemented by a coordinated programme of industry-relevant transferable skills that will prepare them for future careers in the medical technologies sector,” commented enGenes CEO, Dr. Jürgen Mairhofer.
For more information follow https://www.pharmaceutical-networking.com/engenes-participates-in-synbiocarb-initiative/
Comments